From relentless itching and painful flare-ups to sleepless nights and emotional exhaustion, eczema can take a serious toll on ...

More than 31 million people in the U.S. live with eczema, a chronic skin condition that can disrupt daily life yet continues ...

A mum has opened up about her daughter’s eczema struggles, saying it was heartbreaking to see her baby’s sheets splattered ...

Despite being a first-line treatment for CHE, nearly 40% of patients treated with TCS had inadequate treatment response or contraindications to TCS.

Eli Lilly announced on Friday safety and efficacy results from two separate late-stage studies testing its approved drugs for ...

When most people think of eczema, they picture a dry, red, inflamed and itchy rash. But on darker skin tones, eczema can look ...

For readers not familiar with this condition, eczema refers to a group of inflammatory conditions that cause skin to become dry, itchy, flaky and bumpy. The most common form of eczema is atopic ...

Market Implications: The successful development of abrocitinib could enhance Pfizer’s market position in pediatric dermatology, potentially boosting investor confidence and stock performance. Given ...

Nearly 1 in 10 U.S. adults report having physician-diagnosed chronic head eczema, according to findings from a ...

Once-daily, effective, safe, and well-tolerated ZORYVE cream 0.05% now commercially available for children as young as age 2ZORYVE cream 0.05% provides rapid clearance of atopic dermatitisZORYVE can ...

Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a Phase 2B clinical study titled ‘A PHASE 2B, ...

EBGLYSS (lebrikizumab-lbkz) sustained similar levels of skin clearance when administered as a single injection of 250 mg once ...